BORIS in Hormone-Driven Cancers: Epigenetic Reprogramming, Transcriptional Plasticity, and Therapeutic Implications
Cells · 03.11.2026 · 15 (21) · 2001
DOI: 10.3390/cells15212001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 03.11.2026. Verfasst von Sara Saleem und 2 weiteren Autor:innen. Beteiligte Einrichtung: Newcastle University Centre for Cancer, Paul O'Gorman Building, Newcastle upon Tyne NE2 4AD, UK. Hauptthemen laut MEDLINE: Epigenesis, Genetic, DNA-Binding Proteins, Neoplasms, Transcription, Genetic. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of National Unity, Ministry of Higher Education and Scientific Research, Libya.
Abstract (Originalsprache)
Hormone-driven cancers, including prostate, breast, endometrial and ovarian cancers, are a leading cause of cancer-related mortality. Endocrine therapies targeting androgen receptor and oestrogen receptor/progesterone receptor signalling have improved outcomes, but acquired resistance arising through genetic and epigenetic mechanisms that bypass receptor dependence remains a major challenge. BORIS (Brother of the Regulator of Imprinted Sites), a CTCF paralogue, is a germline-restricted regulator that becomes aberrantly reactivated in cancer through promoter hypomethylation, p53 loss, and loss of CTCF-mediated repression. Once expressed, BORIS occupies CTCF sites, displacing or co-occupying them with CTCF, and reprograms clustered sites into alternative transcriptional start sites through SRCAP-mediated H2A.Z deposition, activating germline genes that sustain proliferation, and therapeutic resistance. BORIS expression correlates with poor prognosis in ovarian and endometrial cancers, associates with ER/PR levels in breast cancer, and correlates with Gleason score in prostate cancer. BORIS represses AR signalling in ovarian cancer and inversely correlates with receptor expression in endometrial cancer. Its cancer-testis antigen properties position BORIS as an immunotherapy target, with preclinical vaccine efficacy demonstrated in breast cancer models. This review synthesises the disease-specific evidence positioning BORIS as a driver of transcriptional reprogramming and endocrine resistance, identifies current knowledge gaps, and discusses translational implications of targeting this pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Newcastle University Centre for Cancer, Paul O'Gorman Building, Newcastle upon Tyne NE2 4AD, UK.
- Faculty of Biomedical Sciences, University of Benghazi, Benghazi, Libya.
ORCID-Profile: Sara Saleem, Craig N Robson
Förderung
- Government of National Unity, Ministry of Higher Education and Scientific Research, Libya
Zitieren
APA
Saleem, S., Gaughan, L., & Robson, C. N. (2026). BORIS in Hormone-Driven Cancers: Epigenetic Reprogramming, Transcriptional Plasticity, and Therapeutic Implications. Cells, 15(21), 2001. https://doi.org/10.3390/cells15212001
Vancouver
Saleem S, Gaughan L, Robson CN. BORIS in Hormone-Driven Cancers: Epigenetic Reprogramming, Transcriptional Plasticity, and Therapeutic Implications. Cells. 2026;15(21):2001. doi:10.3390/cells15212001
BibTeX
@article{Saleem2026,
author = {Saleem, Sara and Gaughan, Luke and Robson, Craig N},
title = {BORIS in Hormone-Driven Cancers: Epigenetic Reprogramming, Transcriptional Plasticity, and Therapeutic Implications},
journal = {Cells},
year = {2026},
volume = {15},
number = {21},
pages = {2001},
doi = {10.3390/cells15212001}
}
EUVIMED